Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis
2024

Serum IL-23 Levels and Response to Apremilast in Psoriatic Arthritis

Sample size: 23 publication 10 minutes Evidence: moderate

Author Information

Author(s): De Santis Maria, Tonutti Antonio, Isailovic Natasa, Motta Francesca, Rivara Radu Marian, Ragusa Rita, Guidelli Giacomo M., Caprioli Marta, Ceribelli Angela, Renna Daniela, Luciano Nicoletta, Selmi Carlo

Primary Institution: Humanitas University and IRCCS Humanitas Research Hospital

Hypothesis

Can serum IL-23 levels predict the response to apremilast in patients with psoriatic arthritis?

Conclusion

Serum IL-23 levels can serve as candidate biomarkers for predicting the response to apremilast in patients with psoriatic arthritis.

Supporting Evidence

  • 74% of patients responded to apremilast after 4 months.
  • Higher baseline serum IL-23 levels were associated with better treatment response.
  • Apremilast reduced IL-23 expression in macrophages.

Takeaway

Doctors can check a blood test for IL-23 to see if a medicine called apremilast will work for people with psoriatic arthritis.

Methodology

Patients with psoriatic arthritis were treated with apremilast, and blood samples were analyzed for cytokine levels and expression before and after treatment.

Potential Biases

Potential bias due to concurrent treatments and the small, non-representative sample size.

Limitations

The small sample size and the predominance of oligoarthritis limit the generalizability of the findings.

Participant Demographics

23 patients with psoriatic arthritis (43% women, median age 56 years) and 20 controls with osteoarthritis.

Statistical Information

P-Value

p = 0.003

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1455134

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication